Browse > Article
http://dx.doi.org/10.4014/jmb.1708.08017

Immune Effect of Newcastle Disease Virus DNA Vaccine with C3d as a Molecular Adjuvant  

Zhao, Kai (Key Laboratory of Microbiology, School of Life Science, Heilongjiang University)
Duan, Xutong (Key Laboratory of Microbiology, School of Life Science, Heilongjiang University)
Hao, Lianwei (Key Laboratory of Microbiology, School of Life Science, Heilongjiang University)
Wang, Xiaohua (Key Laboratory of Microbiology, School of Life Science, Heilongjiang University)
Wang, Yunfeng (Division of Avian Infectious Diseases, State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences)
Publication Information
Journal of Microbiology and Biotechnology / v.27, no.11, 2017 , pp. 2060-2069 More about this Journal
Abstract
Newcastle disease is a serious infectious disease in the poultry industry. The commercial vaccines can only offer limited protection and some of them are expensive and need adjuvants. At present, DNA vaccines are widely used. However, the immune responses induced by DNA vaccines are too slow and low. Here, we constructed the transfer vectors with a different number of C3d as molecular adjuvants (n = 1, 2, 4, or 6), and the vectors were cloned into the optimal eukaryotic expression plasmid (pVAXI-optiF) that expressed the F gene of Newcastle disease virus (NDV), and named pVAXI-F(o)-C3d1, pVAXI -F(o)-C3d2, pVAXI-F(o)-C3d4, and pVAXI-F(o)-C3d6, respectively. Cell transfection test indicated that pVAXI-F(o)-C3d6 showed the highest expression. In vivo immunization showed that the chickens immunized with pVAXI-F(o)-C3d6 intramuscularly induced better immune responses than the chickens immunized with the other plasmids. The protective efficacy of pVAXI-F(o)-C3d6 was 80% after challenge with the highly virulent NDV strain F48E9. The results in this study showed that C3d6 could be used as a molecular adjuvant to quickly induce an effective immune response to control NDV.
Keywords
Newcastle disease virus; DNA vaccine; F gene; C3d; molecular adjuvant;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Steglich C, Grund C, Roder O, Zhao N, Mettenleitera TC, Romer-Oberdorfera A. 2014. Chimeric avian paramyxovirusbased vector immunization against highly pathogenic avian influenza followed by conventional Newcastle disease vaccination eliminates lack of protection from virulent ND virus. Trials Vaccinol. 3: 65-72.   DOI
2 Miller PJ, Haddas R, Simanov L, Lublin A, Rehmani SF, Wajid A, et al. 2015. Identification of new sub-genotypes of virulent Newcastle disease virus with potential panzootic features. Infect. Genet. Evol. 29: 216-229.   DOI
3 Hao HF, Chen SL, Liu P, Ren S, Gao X, Wang Y, et al. 2016. Genetic variation in V gene of class II Newcastle disease virus. Infect. Genet. Evol. 37: 14-20.   DOI
4 DiNapoli JM, Ward JM, Cheng L, Yang L, Elankumaran S, Murphy BR, et al. 2009. Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans. Vaccine 27: 1530-1539.   DOI
5 Wu Y, He J, An Y, Wang X, Liu Y, Yan S, et al. 2016. Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy. J. Pharmacol. Sci. 132: 24-30.   DOI
6 Morla S, Shah M, Kaore M, Kurkure NV, Kumar S. 2016. Molecular characterization of genotype XIIIb Newcastle disease virus from central India during 2006-2012: evidence of its panzootic potential. Microb. Pathog. 99: 83-86.   DOI
7 Dimitrov KM, Ramey AM, Qiu X, Bahl J, Afonso CL. 2016. Temporal, geographic, and host distribution of avian paramyxovirus 1 (Newcastle disease virus). Infect. Genet. Evol. 39: 22-34.   DOI
8 Dortmans JC, Rottier PJ, Koch G, Peeters BP. 2010. The viral replication complex is associated with the virulence of Newcastle disease virus. J. Virol. 84: 10113-10120.   DOI
9 Liu XF, Wan HQ, Ni XX, Wu YT, Liu WB. 2003. Pathotypical and genotypical characterization of Newcastle disease virus isolated from outbreaks in chicken and goose flocks in some regions of China during 1985-2001. Arch. Virol. 148: 1387-1403.
10 Wang J, Lv Y, Zhang Y, Zheng D, Zhao Y, Castellan D, et al. 2016. Genomic characterizations of a Newcastle disease virus isolated from ducks in live bird markets in China. PLoS One 11: e0158771.   DOI
11 Nagai Y, Klenk HD, Rott R. 1976. Proteolytic cleavage of the viral glycoproteins and its significance for the virulence of Newcastle disease virus. Virology 72: 494-508.   DOI
12 Cardenas-Garcia S, Diel DG, Susta L, Lucio-Decanini E, Yu Q, Brown CC, et al. 2015. Development of an improved vaccine evaluation protocol to compare the efficacy of Newcastle disease vaccines. Biologicals 43: 136-45.   DOI
13 Suradhat S, Braun RP, Lewis PJ, Babiuk LA, van Drunen Littel-van den Hurk S, Griebel PJ, et al. 2001. Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet. Immunol. Immunopathol. 83: 79-92.   DOI
14 Liu D, Niu ZX. 2008. Cloning of a gene fragment encoding chicken complement component C3d with expression and immunogenicity of Newcastle disease virus F gene-C3d fusion protein. Avian Pathol. 37: 477-485.   DOI
15 Zhang Y, Guo J, Li L, Liu X, Yao X, Liu H. 2016. The solvent at antigen-binding site regulated C3d-CR2 interactions through the C-terminal tail of C3d at different ion strengths:insights from molecular dynamics simulation. Biochem. Biophys. Acta 1860: 2220-2231.   DOI
16 Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. 1996. C3d of complement as a molecular adjuvant:bridging innate and acquired immunity. Science 271: 348-350.   DOI
17 Zhao K, Rong G, Guo C, Luo X, Kang H, Sun Y, et al. 2015. Synthesis, characterization and immune efficacy of LDH@$SiO_2$ nanoparticles with shell-core structure as a delivery carrier for Newcastle disease virus DNA vaccine. Int. J. Nanomedicine 10: 2895-2911.
18 Wang R, Richie TL, Baraceros MF, Rahardjo N, Gay T, Banania JG, et al. 2005. Boosting of DNA vaccine-elicited gamma interferon responses in humans by exposure to malaria parasites. Infect. Immun. 73: 2863-2872.   DOI
19 Li GX, Zhou YJ, Yu H, Tian ZJ, Yan LP, Zhang Q, et al. 2010. Prime-boost immunization with HA/C3d DNA followed by a recombinant pseudorabies virus boost enhanced protective immunity against H3N2 swine influenza virus in mice. Res. Vet. Sci. 88: 345-351.   DOI
20 Musa HH, Zhang WJ, Tao J, Guan YK, Duan XL, Yang Y, et al. 2014. Cloning and expression of FimA-C3d recombinant protein. J. Genet. Eng. Biotechnol. 12: 55-59.   DOI
21 Crepeaux G, Eidi H, David M, Baba-Amer Y. 2017. Nonlinear dose-response of aluminium hydroxide adjuvant particles: selective low dose neurotoxicity. Toxicology 375:48-57.   DOI
22 Buonavoglia D, Greco G, Corrente M, D'Abramo M. 2010. Long-term immunogenicity and protection against Mycoplasma agalactiae induced by an oil adjuvant vaccine in sheep. Res. Vet. Sci. 88: 16-19.   DOI
23 Kumar S. 2015. Newcastle disease virus outbreaks in India:time to revisit the vaccine type and strategies. Vaccine 33:3268-3269.   DOI
24 Cardenas-Garcia S, Dunwoody RP, Marcano V, Diel DG, Williams RJ, Gogal RM Jr, et al. 2016. Effects of chicken interferon gamma on Newcastle disease virus vaccine immunogenicity. PLoS One 11: e0159153.   DOI
25 Wang G, Zhu R, Yang L, Wang K, Zhang Q, Su X, et al. 2016. Non-thermal plasma for inactivated-vaccine preparation. Vaccine 34: 1126-1132.   DOI
26 Kim SH, Samal SK. 2016. Newcastle disease virus as a vaccine vector for development of human and veterinary vaccines. Viruses 8: 2-15.
27 Baxter D. 2007. Active and passive immunity, vaccine types, excipients and licensing. Occup. Med. 57: 552-556.   DOI
28 Xu GL, Zhang KQ, Guo B, Zhao TT, Yang F, Jiang M, et al. 2010. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with C3d as a molecular adjuvant. Vaccine 28: 7221-7227.   DOI
29 Tlaxca JL, Ellis S, Remmele RL Jr. 2015. Live attenuated and inactivated viral vaccine formulation and nasal delivery:potential and challenges. Adv. Drug Deliv. Rev. 93: 56-78.   DOI
30 Ramezanpour B, de Foucauld J, Kortekaas J. 2016. Emergency deployment of genetically engineered veterinary vaccines in Europe. Vaccine 34: 3435-3440.   DOI
31 Li L, Petrovsky N. 2016. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev. Vaccines 15: 313-329
32 Oreskovic Z, Kudlackova H, Krejci J, Nechvatalova K, Faldyna M. 2017. Oil-based adjuvants delivered intradermally induce high primary IgG2 immune response in swine. Res. Vet. Sci. 114: 41-43.   DOI